Literature DB >> 19574481

Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.

Mohamed E Salama, Sabina I Swierczek, Kimberly Hickman, Andrew Wilson, Josef T Prchal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19574481      PMCID： PMC2710950          DOI： 10.1182/blood-2009-03-209593

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.

Authors:  W Ma; H Kantarjian; S Verstovsek; I Jilani; M Gorre; F Giles; J Cortes; S O'Brien; M Keating; M Albitar
Journal:  Br J Haematol       Date:  2006-06-20       Impact factor: 6.998

2.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2007-03-22       Impact factor: 22.113

3.  Higher detection rate of JAK2 mutation using plasma.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Weimin Sun; Arlene M Buller; Iman Jilani; Joyce G Schwartz; Francis Giles; Maher Albitar
Journal:  Blood       Date:  2008-04-01       Impact factor: 22.113

4.  Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.

Authors:  Robert Kralovics; Yongli Guan; Josef T Prchal
Journal:  Exp Hematol       Date:  2002-03       Impact factor: 3.084

5.  Polycythemia vera is not initiated by JAK2V617F mutation.

Authors:  Roberto H Nussenzveig; Sabina I Swierczek; Jaroslav Jelinek; Amos Gaikwad; Enli Liu; Srdan Verstovsek; Jaroslav F Prchal; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

6.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Authors:  Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2007-08-21       Impact factor: 22.113
  6 in total
  1 in total

Review 1.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.